Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Outcome of interim multidrug-resistant tuberculosis treatment in Yemen

Ammar Ali Saleh Jaber , Baharudin Ibrahim

Department of Clinical Pharmacy, School of Pharmaceutical Sciences, R06;Universiti Sains Malaysia, Penang, Malaysia;

For correspondence:- Ammar Jaber Email: amarali20142015@gmail.com Tel:+60174673989

Accepted: 29 July 2019 Published: 29 August 2019

Citation: Jaber AA, Ibrahim B. Outcome of interim multidrug-resistant tuberculosis treatment in Yemen. Trop J Pharm Res 2019; 18(8):1755-1762 doi: 10.4314/tjpr.v18i8.27

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To assess the interim therapy outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) in Yemen.

Methods: This study was performed in four major tuberculosis (TB) centers in Yemen, namely, Alhodidah, Taiz, Sana’a, and Aden. Data were collected between January 1, 2014 and December 31, 2016, and consistent methods were adopted to obtain data from MDR-TB patients. The standardized WHO method of calculating and reporting the interim therapy outcomes patients enrolled in the study was applied, and the relation between dependent and independent variables was obtained by logistic regression.

Results: A total of 85 MDR-TB cases were reported between January 1, 2014 and December 31, 2016. Of these cases, 62 reported available interim results. Among the 62 MDR-TB cases, only 40 (64.5 %) were categorized into successful interim therapy outcome group. This study found a baseline weight ≤ 40 kg, comorbidity, and first-line drug (FLD) resistance (> 3) as risk factors influencing unsuccessful interim therapy outcomes.

Conclusion: This cohort study reports an alarmingly high rate of unsuccessful interim therapy outcomes among Yemeni MDR-TB patients. Enhancement of the clinical management of patients with a baseline weight ≤ 40 kg, comorbidity, and FLD resistance (>3) may improve TB therapy outcomes.

Keywords: Multidrug resistance, Khat, Tuberculosis, TB